Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial
Auteurs / Authors: Gerard Zalcman, Anne Madroszyk, Charles Dayen, Olivier Molinier, Thomas Egenod, Didier Debieuvre, Sophie Beaucaire-Danel, Adrien Dixmier, Eric Pichon, Sigolène Galland-Girodet, Etienne Giroux Leprieur, Nicolas Cloarec, Jacques Cadranel, Josiane Otto, Nicolas Poté, Alexandra Langlais, Franck Morin, Martine Antoine, Virginie Westeel, Anne-Claire Toffart
Journal / Conference: ASCO
Année / Year: 2023
PMID: Poster session
Lien vers la publication: https://meetings.asco.org/abstracts-presentations/226548
